Abstract
Relapse due to either residual host disease or reinfused tumor cells remains the principal cause of treatment failure after autologous stem cell transplantation. Although it is intuitively attractive to remove putative tumor cells from autologous grafts prior to transplant and more than 1000 articles have been written on the subject, there are only limited data suggesting that purging autografts has any favorable effect on relapses or disease-free survival. Certain purging techniques that remove substantial numbers of T cells or destroy progenitor cells may have adverse effects such as delayed hematopoietic or T cell reconstitution. There is a critical need for large, well-designed trials that specifically address the value of a particular purging technique on relapses and disease-free survival after autologous stem cell transplant.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bensinger, W. Should we purge?. Bone Marrow Transplant 21, 113–115 (1998). https://doi.org/10.1038/sj.bmt.1701051
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701051
Keywords
This article is cited by
-
Viral purging of haematological autografts: should we sneeze on the graft?
Bone Marrow Transplantation (2007)
-
Autologous stem cell transplantation in follicular non-Hodgkin's lymphoma
Bone Marrow Transplantation (2002)
-
In vivo purging and relapse prevention following ASCT
Bone Marrow Transplantation (2002)
-
Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia
Leukemia (2002)
-
DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma
Bone Marrow Transplantation (2001)